Department of Pathology, Showa University School of Medicine, Tokyo, Japan.
Division of Hematology, Department of Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-Ku, Tokyo, 142-8666, Japan.
Int J Hematol. 2019 May;109(5):539-544. doi: 10.1007/s12185-019-02616-y. Epub 2019 Mar 7.
Aberrant expression of the interleukin-3 receptor alpha chain (IL3RA or CD123) is frequently observed in patients with a subset of leukemic disorders, including acute myeloid leukemia (AML), particularly in leukemia stem cells. We analyzed the relationships between immunohistochemical (IHC) expression, including that of CD123, and clinical outcomes. This study involved a retrospective analysis of 48 patients diagnosed with de novo AML (M0-M5, n = 48) at our hospital between February 2008 and September 2015. Among patients with de novo AML, CD123 expression was associated with a failure to achieve complete response (CR) to initial induction chemotherapy (P = 0.044) and poor overall survival (OS) (P = 0.036). This is the first study using IHC to demonstrate that CD123 expression is associated with a poor CR rate and poor OS in de novo AML patients. These results support previous reports using flow cytometry (FCM). CD123 expression may thus be useful for assessing AML patients' prognoses. At the time of diagnosis, CD123 expression analysis using IHC may represent a clinically useful assessment for de novo AML patients.
白细胞介素-3 受体 α 链（IL3RA 或 CD123）的异常表达在一组白血病疾病患者中经常观察到，包括急性髓细胞白血病（AML），尤其是白血病干细胞中。我们分析了免疫组织化学（IHC）表达，包括 CD123 表达，与临床结果之间的关系。本研究回顾性分析了 2008 年 2 月至 2015 年 9 月在我院诊断为初发 AML（M0-M5，n=48）的 48 例患者。在初发 AML 患者中，CD123 表达与初始诱导化疗未能达到完全缓解（CR）（P=0.044）和总生存（OS）不良（P=0.036）相关。这是首次使用 IHC 证明 CD123 表达与初发 AML 患者 CR 率低和 OS 差相关的研究。这些结果支持使用流式细胞术（FCM）的先前报告。因此，CD123 表达可能有助于评估 AML 患者的预后。在诊断时，使用 IHC 进行 CD123 表达分析可能代表初发 AML 患者的一种临床有用的评估方法。
